Creatine monohydrate is the most-tested, most cost-effective, and most efficacious form of creatine. A pooled meta-analysis spanning >13,000 participants, doses from a few grams up to 30g/day, ages teens–77, and durations from a few weeks up to 14 years found adverse-event-reporting rates statistically indistinguishable between creatine and placebo (~13% each), including for the most commonly reported effects (cramping, GI distress). Side effects screened across the pooled studies included vertigo, hypertension, headache, dizziness, nausea, diarrhea, impaired concentration, sleep disturbance, edema, palpitations, cardiac events, kidney issues, and elevated liver enzymes — none showed a creatine-vs-placebo difference. A long-duration Parkinson's trial (10g/day for up to 8 years) extends the safety data to a multi-year timeline across a wide range of organ-system complaints (renal, hepatic, cardiac, psychiatric, etc.).
See Evaluating Nutrition & Fitness Evidence for how the "no significant difference from placebo" finding gets framed as "causation disproven" rather than "insufficient evidence of causation."
No safety differences were found across forms in the cited meta-analysis; the case for monohydrate rests on efficacy and cost, not safety.
Creatine acts as an osmolyte, pulling water into muscle cells — increasing total body water and intracellular water specifically, not extracellular water. This is framed as a desirable mechanism tied to anabolic effect rather than an unwanted side effect: products marketed as "not causing water retention" are read as either misrepresenting the product or effectively admitting it isn't anabolic.
A 2026 randomized 4-arm trial in resistance-trained men (placebo, creatine HCl at 0.3 g/kg/day no loading, creatine monohydrate with 5-day loading then maintenance, creatine monohydrate no loading; 8 weeks) found creatine monohydrate remains the benchmark that newer "improved" creatine forms fail to beat. All creatine arms outperformed placebo on leg press strength, bench press strength, and cross-sectional area increases, but no single outcome measure distinguished HCl from monohydrate — undercutting HCl's marketing claim that its higher solubility yields greater bioavailability and therefore better results at a lower dose. The study intentionally used a low maintenance dose (~2.1 g/day) specifically to give any solubility-driven bioavailability edge the best chance of appearing (see Evaluating Nutrition & Fitness Evidence on dose selection as a sensitivity lever) — a high-dose ceiling effect could otherwise mask a real difference, so the null result here is more probative than a same-outcome result at high doses would be.
This is the latest cycle in a recurring pattern: monohydrate's ~30-40 years of evidence and its commodity status (widespread manufacture) has driven its price down and removed profit margin, creating a recurring commercial incentive to market "improved" forms against a new alleged flaw of monohydrate:
For solubility/mixing complaints specifically (the stated rationale for switching to HCl), two lower-cost fixes stay within monohydrate: dissolve it in an acidic liquid (e.g., orange juice — monohydrate is more soluble and stable in acidic solution), or use micronized monohydrate for finer mixing.
In the same trial, the 5-day loading-phase group (0.3 g/kg/day) showed no outcome difference from the non-loading monohydrate group by week 8 — loading only changes time-to-saturation, not end-state strength or cross-sectional area. Skipping loading is a valid default if you don't mind ~2 extra weeks to reach full muscle saturation.
A 2026 12-week resistance-training study (untrained men and women, preceded by a 1-week creatine-or-placebo wash-in) found creatine's ~0.5 kg lean-mass advantage over placebo appeared entirely during the 1-week wash-in, with no further divergence between groups over the subsequent 12 weeks of training. Per Layne Norton, this doesn't debunk creatine — he cites "mountains of data" for lean mass, strength, and performance benefits — but suggests the benefit is front-loaded: creatine is an osmolyte that pulls water into muscle cells, and once intracellular water reaches a new steady state, continued training doesn't add further measurable divergence between groups. This is an instance of the general baseline-reset pattern — see Evaluating Nutrition & Fitness Evidence for the caffeine analogy Norton uses to generalize it.
Norton frames intracellular water retention as inseparable from creatine's anabolic mechanism itself: muscle cells are ~70% water/fluid, so more intracellular fluid means bigger cells by default. He argues "special" creatine forms marketed as not causing water retention are therefore, by his own logic, implicitly claiming to not be anabolic — and no evidence supports the no-water-retention claim for those products.
Practical guidance reiterated: use only creatine monohydrate (no evidence-backed reason to prefer alternative forms); standard dose 5g/day; those with GI discomfort can split into half-dose AM / half-dose PM. Key limitation: the study used untrained subjects, whose large general response to any resistance training may have washed out or masked an ongoing creatine effect during the 12-week phase — trained individuals might show a different (continuing) divergence.
Disclosure: Norton has a financial conflict of interest — his supplement line Outwork Nutrition sells a creatine-monohydrate-containing product ("Recovery").
A study reported by coach Layne Norton (Biolayne) tested a single acute high dose of creatine monohydrate — 0.35 g/kg (~30+ g for a ~200 lb adult) — given 3–4 hours before cognitive testing in subjects sleep-deprived for 21 hours. The dose attenuated (but did not fully reverse) sleep-deprivation-induced declines in brain metabolites, brain pH, and cognitive test performance.
This is a distinct mechanism from creatine's well-established chronic muscle benefits (lean mass, strength, performance), which require ~5 g/day dosing over weeks to saturate muscle phosphocreatine stores — a single dose does not produce those effects. Practical takeaway floated by Norton: a high one-time dose may help offset cognitive impairment after an all-nighter, during high-stress/poor-sleep stretches, or before a task demanding acute cognitive performance.
Open question, flagged explicitly as speculation rather than established fact: whether people already creatine-loaded (saturated muscle phosphocreatine stores) get the same acute cognitive boost from a high one-time dose — muscle and brain/CNS creatine saturation kinetics may not track each other, given the blood-brain barrier's selectivity. Relatedly, muscle-saturated 'non-responders' to creatine's physical benefits may still see cognitive benefits from acute high dosing, suggesting the cognitive and physical benefit pathways may be at least partly independent. See also Brain-Support Nutrient Compounds & Dosing.
Monohydrate vs. alternatives: creatine monohydrate remains, per Norton, the safest, cheapest, and best-supported form regardless of angle (physical or cognitive) — it's stable in stomach acid (no buffering needed), and studies comparing pH-buffered creatine to plain monohydrate show equivalent benefit despite buffered versions costing 3–4x more. Creatine ethyl ester (popular ~2010s) has lower bioavailability than monohydrate. Creatine HCl is more soluble/easier to mix and may allow a smaller effective dose, but per-effective-dose is still pricier than monohydrate; sensible mainly for people who are GI-sensitive to creatine. For GI sensitivity, recommendation is micronized monohydrate split into smaller doses (e.g., two 2.5 g or 1–2 g doses) rather than one 5 g dose, plus adequate water intake — in the sleep-deprivation study's ~30 g acute dose, no participant reported GI side effects.
Food sourcing is impractical: only ~1–1.5 g creatine per pound of red meat, ~50% destroyed by cooking, requiring ~7 lbs of red meat/day to match a standard supplemental dose — far more expensive than supplementing. This directly rebuts claims (e.g., Paul Saladino on The Joe Rogan Experience) that a meat-based diet obviates creatine supplementation.
Hair-loss myth: the persistent claim that creatine causes hair loss traces to a single, never-repeated 2009 mechanistic study showing increased DHT with creatine supplementation — it did not directly measure hair loss and showed no change in any other sex hormone. If the DHT/hair-loss effect were real, follow-up studies would have confirmed it by now; none have. More broadly, the major historical safety concerns about creatine (kidney harm, liver harm, increased disease risk) have been put to rest by current data. This single-study-caution pattern is a good example of Evaluating Nutrition & Fitness Evidence in practice.
The claim that creatine monohydrate causes hair loss traces to a single ~20-year-old study: 3 weeks of creatine loading in rugby players, small sample, that found increased DHT but no change in testosterone or free testosterone. Critically, that study never measured hair loss or hair growth — it measured a hormonal precursor and the loss claim was inferred from there. See Evaluating Nutrition & Fitness Evidence for why that inference doesn't hold.
A newer double-blind, placebo-controlled RCT closes the gap: 5g/day creatine monohydrate vs. 5g/day maltodextrin placebo, 12 weeks of resistance training, with hair growth/loss measured directly this time. Result: no difference between groups in hair growth or loss, DHT, testosterone, or free testosterone. In both groups (creatine and placebo alike), total testosterone rose and free testosterone fell over the 12 weeks — consistent with the resistance-training stimulus itself rather than creatine, and DHT was flat in both groups at baseline and endpoint.
Layne Norton (PhD), summarizing: "You cannot claim something does X if you don't actually measure X" — and states he'd revise his position given five more studies showing hair loss from creatine, but that the current direct evidence says it does not.
Quote: "Can we please stop saying that creatine causes hair loss? There is no evidence to support this and all of the direct evidence we do have says that it does not."
Creatine monohydrate remains the reference form; alternative forms (ethyl ester, buffered creatine, creatine hydrochloride) are argued to be commercial plays rather than efficacy gains, since monohydrate is commoditized (many sellers, thin margins) and harder to differentiate profitably.
Quote: "If you are saying that your creatine does not cause water retention, you are actually saying that your creatine is not anabolic."
Standard muscle-saturation doses of creatine (~5g) are consumed by muscle tissue before meaningfully raising brain creatine — muscle acts as a "greedy," competitive sink for supplemented creatine. Raising brain creatine appears to require substantially higher intake.
A widely cited "10g" threshold for brain creatine (repeated by Dr. Rhonda Patrick, citing a German study) is a mis-citation: the actual study (Tübingen, Germany, ~30 years old, no control group, small n) used 20g/day split-dose for 4 weeks, after which MRI-measured brain creatine rose from baseline and fell again by week 16 post-cessation. A separate placebo-controlled trial in adolescent girls with treatment-resistant depression tested 2g/4g/10g over 8 weeks and measured phosphocreatine; the 10g arm had the largest raw increase but didn't reach statistical significance versus the other doses — consistent with 10g being an unreliable threshold and 20g+ being the more robust target for raising brain creatine. See Evaluating Nutrition & Fitness Evidence for the general lesson about verifying cited study parameters.
Acute cognitive protection under sleep deprivation: A single (not repeated) placebo-controlled dose of 0.35 g/kg creatine (~20–28g depending on body weight) given to subjects sleep-deprived for 21 hours prevented cognitive decline on all measured tests and improved performance on some vs. baseline — sleep-deprived, creatine-supplemented subjects outperformed rested, non-supplemented subjects on some cognitive measures. This is a single acute high dose, distinct from daily brain-loading protocols. See Brain-Support Nutrient Compounds & Dosing.
Reviewed by Physionic (Dr. Nick) against Dr. Rhonda Patrick's claims on the Huberman podcast; Physionic found both claims essentially correct, with the specific "10g" number being the one inaccuracy (the source study used 20g).
An animal study (creatine-supplemented diet vs. identical control diet, brain cells analyzed directly — the kind of invasive measurement that can't be done in humans) found creatine acts on the brain through at least two distinct cellular mechanisms:
Both effects are component-specific rather than global, and together suggest creatine's brain benefit isn't one pathway but several (energy conversion + receptor/synapse stabilization) acting in parallel. Per Evaluating Nutrition & Fitness Evidence, mechanistic/animal findings like these can't be applied on their own — they only support real-world conclusions when combined with separately-established human clinical data on creatine and cognition.
Creatine's cognitive benefits appear concentrated in populations under metabolic or cognitive stress — sleep deprivation, hypoxia, jetlag, or aging (generally 60+) — rather than in unstressed populations, per creatine researcher Dr. Darren Candow (via Rhonda Patrick's podcast). Mechanistically, creatine taken up by neurons is phosphorylated into phosphocreatine, a fast-acting reserve energy buffer that regenerates ATP within seconds of neuronal firing; the brain consumes ~20% of daily energy, which is part of why this reserve matters there.
The science-communicator channel Physionic flagged the specific meta-analysis Candow cited as methodologically flawed rather than disputing the underlying claim: it double-counts the same underlying trials (e.g., the Alvis and McMorris studies) by treating multiple measurements from one trial as separate entries, inflating apparent participant counts up to 7x and manufacturing a pooled "effect" on memory that isn't replicated in other outcomes (e.g., processing speed) within the same analysis. See Evaluating Nutrition & Fitness Evidence for the general red-flag pattern this illustrates.
Despite discarding this specific meta-analysis as evidence, Physionic maintains the underlying cognitive effect is likely real, citing other corrected analyses and independent RCTs.
Dosing conundrum: standard muscle-building protocols use ~5g/day with no loading phase required. The best brain-focused studies, however, reportedly use ~20g/day for at least a week to see effects — a much higher dose than muscle needs. The likely reason: the blood-brain barrier's astrocyte layer has limited or no expression of the creatine transporter (unlike the endothelial cells on the blood side, which do express it), so low blood creatine concentrations from a 5g dose may not cross effectively into the brain. The mechanism by which higher blood concentrations eventually do cross the astrocyte barrier is still not well understood. Current assessment (as of this source): some evidence, not yet strong evidence, that 20g may outperform 5g for brain-specific benefits. See Brain-Support Nutrient Compounds & Dosing for how this compares to other cognition-focused supplement dosing.
A physician source who recommends creatine broadly to patients and family nonetheless declines to take it himself — illustrating that population-level safety data doesn't automatically resolve an individual's risk calculus.
The creatinine confound. Creatine converts partly into creatinine, the same molecule used as the standard biomarker for kidney function (GFR estimation). Supplementation can therefore artificially elevate creatinine readings, making kidney function look worse than it actually is — a measurement-artifact confound, distinct from true kidney harm. A separate, more substantive concern is that excreting the extra creatinine load could itself add metabolic burden to the kidneys over time.
What the safety data actually covers. Trials spanning 5 days to 5 years, at doses of 5-30 g/day, show no measurable effect on GFR or other kidney-function indices — but these were run in people with healthy kidneys. There is little to no safety data for creatine in any pre-existing kidney disease, and none identified specifically for polycystic kidney disease (PKD) — a genetically inherited condition with slow, usually asymptomatic cyst growth that can progress to kidney failure, often not manifesting until the 60s-70s.
Personal vs. population calculus. Given a family history of PKD, the source's personal decision differs from his own population-level recommendation: he treats the absence of safety data (not evidence of harm) as sufficient reason for personal caution, while still judging the risk/benefit favorable for the general population — especially older, healthy adults who train. His stated fallback is to pursue the same ends (muscle/fat outcomes, cognitive support, glucose control) through harder training and stricter lifestyle discipline instead, accepting a slower timeline in exchange for avoiding an untested exposure. See Evaluating Nutrition & Fitness Evidence for the general reasoning pattern this illustrates.
Supporting evidence cited. A meta-analysis of RCTs found creatine supplementation increased fat-free mass by ~0.8 kg and reduced body fat by ~0.28% on average, strengthening with resistance training (see Body Recomposition (Recomp) Without a Caloric Deficit); vegetarians/vegans may see larger effects due to lower baseline dietary creatine intake; and one RCT found creatine supplementation lowered HbA1c and post-meal glucose in diabetics.
The claim that creatine supplementation causes hair loss traces almost entirely to one small, unreplicated 2009 randomized trial of 20 college-age male rugby players (25g/day loading week, then 5g/day maintenance for two weeks, vs. placebo). Total testosterone was unchanged, but DHT (dihydrotestosterone, a testosterone byproduct) rose 56% after the loading week and stayed ~40% elevated after the full 3 weeks. Mechanistically, testosterone converts to DHT via an enzyme, and DHT binds the androgen receptor in hair follicles, causing miniaturization (thinner, weaker hair, shortened growth cycle) — but only in people with genetic susceptibility to male pattern baldness.
Critically, the 2009 trial never measured hair itself — no counts, density, or thickness, only blood hormone levels. And despite the reported percentage jump, all DHT values stayed within the normal clinical range (~0.98 → 1.5 → 1.4, vs. a normal range up to 2–3). The finding has never been reproduced by another trial. A 2021 review paper on frequently asked creatine questions concluded there is no convincing evidence linking creatine to hair loss, and proposed regression to the mean as a statistical explanation: the placebo group started with numerically higher baseline DHT (1.26) than the creatine group (0.98), a non-significant difference that may have exaggerated the apparent divergence over time. As of 2021 the causal question had never been tested directly — see Evaluating Nutrition & Fitness Evidence for the general pattern of a single small study driving a widely circulated claim.
The first (and so far only, as of this writing) direct test of hair outcomes was a randomized controlled trial published April 2025: 38 men given 5g/day creatine or placebo for 3 months. No significant difference between groups in free testosterone, total testosterone, DHT, or hair parameters (hair count, density, thickness) — a trial four times longer than the original rugby study. Key limitation: it used a flat 5g/day dose and did not replicate the original 25g/day loading-week protocol, so a higher loading dose's effect on hair remains untested. Current evidence does not support creatine causing hair loss at typical maintenance doses (5g/day) over 3 months; higher-dose loading and longer-duration exposure remain open questions.
Creatine monohydrate remains one of the most studied and safest sports supplements; the 1980s gym-culture belief that 'creatine phosphate' is superior to monohydrate, requiring a 20-30 g/day loading phase for two weeks, is outdated. A flat 5 g/day (no loading) saturates muscle within 3-4 weeks with less GI distress; loading is only useful ahead of imminent competition.
Mechanism: creatine regenerates ATP via phosphocreatine, adding 1-2 extra reps per set rather than directly boosting muscle protein synthesis in sedentary people — strength/muscle gains come from the extra training volume it enables (compare Training to Failure & Stimulus-to-Fatigue Ratio). Vegetarians/vegans, who rely entirely on endogenous synthesis with no dietary meat source, show disproportionately large benefits from supplementation.
Brain uptake appears to require a higher dose (~10 g/day split) than muscle saturation (5 g/day), because muscle 'greedily' absorbs most of a standard dose first — many null brain-effect studies may simply have been underdosed. Creatine's brain benefits (processing speed, memory) emerge specifically under stress (sleep deprivation, psychological/emotional stress, neurodegenerative disease), paralleling how it helps muscle specifically under training stress. A pilot study found high-dose creatine (20 g) improved cognitive function in Alzheimer's patients, framed within an 'Alzheimer's as an energy crisis' hypothesis — the brain uses ~20% of total caloric intake despite being <2% of body weight — addressable years before diagnosis.
Kidney safety: creatine does not damage kidneys; elevated creatinine in supplement users is a measurement artifact of the supplementation itself, not renal impairment — cystatin C is the more accurate kidney marker in this population.
Product quality: ~95% of tested creatine gummy products were found to contain essentially no real creatine; capsules and other poorly manufactured formats are also unreliable. Plain monohydrate powder with NSF certification (or Creapure) is recommended. Pediatric/adolescent dosing scales to ~0.1 g/kg body weight rather than flat adult dosing.
Mechanism. Creatine works by supplying phosphocreatine, which acts as a phosphate donor to rapidly regenerate ATP. This maps directly onto ~10-second all-out efforts (e.g. a 40-yard dash) — the phosphagen system — not the oxidative/aerobic pathway. Consistent with this, creatine improves muscle performance (power, hypertrophy, high-intensity/anaerobic output) by roughly 5-10%, sometimes up to 15%, but a meta-analysis found no endurance benefit for trained athletes: it does not augment aerobic capacity.
Dosing. Two historical protocols exist: a loading phase of ~20 g/day, or simply starting at a 3-5 g/day maintenance dose and reaching saturation more slowly. Effectiveness plateaus at 3-5 g/day — higher doses don't outperform it once muscle creatine stores are saturated. No biomarker exists to track individual tissue saturation, so dosing stays protocol-based rather than personally titrated — the same gap flagged by the "biomarker" question in the six-question supplement evaluation framework.
Clearance & the creatinine confound. Once muscle stores are saturated, excess creatine is metabolized by the liver and cleared by the kidneys. High-dose creatine elevates serum creatinine — a standard marker doctors use to assess kidney function — which can read as a false signal of kidney dysfunction on routine blood work. Practical protocol: disclose creatine use to the ordering doctor before any metabolic panel, and if kidney function is imperfect, wash out for 1-2 weeks before the draw.
Sourcing. Creatine monohydrate is the only form with evidence behind it — inexpensive, and the standard to buy with no fillers; the sole ingredient on the label (flavoring aside) should be creatine monohydrate.
Sex-specific and hormonal-transition effects. Women may see more benefit per dose than men — not because the dose differs (the same absolute amount is still recommended) but because women have lower baseline creatine stores tied to smaller average muscle mass, so the same dose produces a larger relative effect. Creatine may help across periods of rapid hormonal change (menstrual cycle, pregnancy, perimenopause, menopause), with weak evidence for reduced depression in women. Pregnancy safety data is insufficient, so the default stance is to discontinue creatine — like any non-essential medication or supplement — for the ~9-month pregnancy window.
Cognitive and recovery evidence (newer, more tentative). A 2024 meta-analysis of 16 RCTs found a positive effect of creatine on memory, and a 2017 review found creatine helps injury prevention and recovery — both positioned as emerging rather than as settled as the muscle-performance evidence.
Overall risk-reward. Run through the six-question framework, creatine lands as low-risk, modest-reward: robust safety data, a well-understood mechanism, and a real but moderate effect size.
Creatine's cognitive effects are harder to establish than its muscle effects: physical performance gains are easy to prove objectively in a short (~12-week) study, but cognitive benefit is proposed to be conditional rather than universal.
Stress-gating model. Creatine crosses the blood-brain barrier, but at doses around the standard 5g/day, muscle tissue is "greedy" and preferentially consumes creatine before enough reaches the brain — especially in people who train. Rhonda Patrick argues this creates a dosing confound in the existing literature: a study run at 5g/day that finds no cognitive effect risks a false-negative conclusion, because the brain may simply have been under-dosed. She argues doses well above 5g (10g+, up to 20g/day in some protocols) are needed for brain-relevant effects.
Even at adequate dose, the benefit is framed as working "in the background of stress" — analogous to how muscle needs mechanical stress (exercise) to convert creatine into a strength gain. "Brain stress" in this framing includes: sleep deprivation, psychological/emotional stress, exam-type stress, aging, and neurodegenerative disease. Rationale offered: the brain consumes ~20% of total caloric intake despite being under 2% of body weight, so supplemental creatine (faster ATP/energy recycling) should help most when brain energy demand is already elevated — not as a general-population nootropic. See Brain-Support Nutrient Compounds & Dosing for how this fits the broader dosing-threshold pattern seen in other brain-support compounds.
Evidence base (early-stage). A small pilot study (researchers described as relatively unknown) gave Alzheimer's patients 20g/day of creatine with an apparent placebo control and found improved cognitive function; combined with exercise, the same patients also gained strength and lean body mass. Older-adult cohorts more broadly appear to benefit from supplemental creatine, framed as aging itself constituting a form of brain stress. This evidence is early and thin — one small pilot study plus aging-cohort observation plus personal anecdote, not RCT-level confirmation. See Evaluating Nutrition & Fitness Evidence.
Prevention framing. Peter Attia frames Alzheimer's prevention — intervening 10-20 years before onset in people most susceptible — as the most important and hardest-to-study question, distinguishing inflammatory, lipid/vascular, and metabolic paths to the disease. Creatine-as-ATP-substrate is positioned as a candidate intervention for a hypothesized metabolic subtype, started years to decades before disease onset — a prevention hypothesis, not a proven treatment. See Longevity Intervention Classification Frameworks.
Practical dosing (Rhonda Patrick's stated position/protocol). She states there is "really no downside" to 10g/day and predicts 10g will replace 5g as the new baseline recommended dose — a personal-practice position that runs ahead of formal dosing guidelines rather than being trial-derived. Her own protocol: 5g doses (to avoid GI issues from one large dose), mixed into water or tea, taken mostly before noon; she raises her dose to 15-20g/day under added stress (e.g., jet lag/sleep deprivation after travel). She reports avoiding afternoon sleepiness when taking more than 5g, but flags this could be placebo and says that wouldn't matter since the effect works for her either way.
A widely-cited case from testing lab Light Labs: the top-selling creatine gummy on Amazon tested at 0% of its claimed creatine, despite positive consumer reviews (explained as placebo effect, since creatine's physiological effects aren't easily self-verified day to day). The high retail price of creatine gummies (~$40) combined with creatine being the most expensive component is cited as the economic driver of the fraud. Plain powder creatine (scoop-in-a-bag format) is described as much lower fraud/degradation risk than gummies, which have more failure points across manufacturing and shelf life. See Supplement Fraud & Quality Verification for the broader verification framework (COA, GMP, stability studies).
Creatine ethylester (CEE) was marketed as more lipophilic than creatine monohydrate and able to bypass the creatine transporter for better cellular uptake. In practice, per Mike Israetel (RP Strength), CEE breaks down in the acidic stomach into creatinine before it can leverage that theoretical advantage — most of it is excreted rather than absorbed ("you will consume it and then it will 30 minutes later come out of your asshole, roughly the same"). He reports no felt training effect from it and advises skipping it in favor of monohydrate.
Creatine monohydrate remains the reference form: cheapest, most heavily researched ("unbelievable amounts of data"), safest, and most effective — "that's how grandma did it."
See Evaluating Nutrition & Fitness Evidence for the self-test heuristic ("if you can't tell at all when very keenly paying attention, probably not doing shit") used to write off CEE.
Creatine monohydrate directly increases intracellular muscle cell swelling — osmolyte-driven water pull into the muscle fiber — and this swelling itself drives growth via the SWELL1/VRAC → mTORC1 sensor pathway, independent of taking on more training volume, training closer to failure, or doing more reps. This distinguishes creatine from most pump supplements, which mainly cause vasodilation (swelling of blood vessels/interstitial space around the fiber) rather than true intracellular cell swelling, and so don't reliably cause growth the same way. Per RP Strength's Dr. Mike, creatine's growth effect is described as near-guaranteed (roughly 9-out-of-10) compared to pump supplements' unreliable direct effect.
Creatine is one of the few supplements with strong evidence behind it, but lifters — including people in the science-based lifting community — tend to overestimate its magnitude. Real-world effect: roughly a 2-3 lb increase in lean mass.
For comparison, a steroid cycle can add 10-20 lbs of lean mass in a month or two — creatine's contribution is real but modest by comparison. This mirrors the broader "temper your expectations, it isn't that it doesn't work" framing Nippard applies across top-tier supplements and surplus size alike — see Caloric Surplus Size & Bulking Strategy and Caffeine as an Ergogenic Supplement.
Bryan Johnson's team ('Don't Die' podcast) recommends ~0.1g/kg bodyweight/day (roughly 5–7g for an average adult) rather than the classic loading protocol (20g/day for 5–7 days). At steady daily dosing, muscle saturation occurs naturally over 3–4 weeks without a loading phase; loading is reserved for cases needing fast saturation and comes with more water-retention side effects.
A widely-covered 12-week study found 5g/day creatine produced no muscle-mass advantage over training alone (both groups gained ~2kg lean mass). The Don't Die team argues this null result is likely a methodology artifact: the study's 7-day washin period (meant to control for water-retention-driven early weight gain) is too short, since actual muscle saturation at 5g/day takes 3–4 weeks — so the study may have measured before saturation was reached rather than showing creatine doesn't work. See Evaluating Nutrition & Fitness Evidence for the general lesson on checking a study's measurement window against the intervention's physiological timescale. Despite this specific null finding, creatine is described as having more supporting data than almost any other supplement, with positive findings across longevity, cognition, bone/muscle health, and metabolic health, and no studies showing harm.
Из тем: Unsorted, Creatine Fundamentals